The Nisa Maruthur Lab studies primary care; individualized medicine for the prevention and treatment of type 2 diabetes and obesity; pharmacogenomics of type 2 diabetes; and comparative effectiveness.

The Mathioudakis lab is focused on developing and evaluating clinical decision support systems, technology, and mHealth for diabetes prevention and management. Our lab leverages large electronic medical record databases and uses machine learning algorithms and artificial intelligence to identify patterns in clinical care associated with optimal clinical outcomes. We are interested in understanding the role that advanced diabetes technologies can play in improving health outcomes for patients with diabetes. Our lab has published extensively on outcomes related to diabetes prevention and diabetes management and outcomes. Based on data from our long-term (over 10 year) clinic-based prospective cohort study from the Johns Hopkins Multidisciplinary Diabetic Foot and Wound Clinic, we have published extensively on clinical predictors and outcomes of patients with diabetic foot ulcers, focusing specifically on the role that glycemic control plays in patients with this complication. Healthcare disparities exist throughout medicine, but are particularly prominent in diabetes; our lab has evaluated healthcare inequities in diabetes outcomes and is developing and evaluating strategies to overcome them. In addition to identify optimal management approach to diabetes and its complications, our lab is interested in development and evaluation of innovative technology approaches to diabetes prevention.

Research in the Kendall Moseley Lab is focused on the interplay between type 2 diabetes, aging and osteoporosis. We also study the function of bone stem cells in the regulation of bone remodeling.

Our research interest is crystalized into three main areas: 1. Type-1 diabetes - Our focus is on understanding how the Fas death pathway regulates the disease and how extracted information can be used to protect high risk individuals and those with new-onset disease. 2. Type 2 diabetes and Obesity - Our lab is studying the role of heparan sulfate proteoglycans (HSPG) in regulating body fat and glucose clearance. 3. Double negative ??T cells - Our studies suggest a critical role for these cells in protecting kidneys from Ischemia reperfusion injury (IRI). Our current focus is understanding their origin and physiological functions.

Researchers in the Suzanne Jan de Beur Lab are interested in bone and mineral metabolism, endocrinology and osteoporosis. In addition, we focus on hormonal regulators of phosphate homeostasis, parathyroid hormone signaling and the molecular basis of hypophosphatemic disorders.

The Wong Lab seeks to understand mechanisms employed by cells and tissues to maintain metabolic homeostasis. We are currently addressing how adipose- and skeletal muscle-derived hormones (adipokines and myokines), discovered in our lab, regulate tissue crosstalk and signaling pathways to control energy metabolism. We use transgenic and knockout mouse models, as well as cell culture systems, to address the role of the CTRP family of hormones in physiological and disease states. We also aim to identify the receptors that mediate the biological functions of CTRPs.

Research in the Mark Sulkowski Lab focuses on hepatitis B and hepatitis C. We've conducted clinical research related to the management of viral hepatitis, including novel agents. Other studies focus on adult patients at the Johns Hopkins site of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Hepatitis B Clinical Research Network as well as the National Institute of Allergy and Infectious Diseases Adult AIDS Clinical Trials Group.

The Michael Klag Lab focuses on the epidemiology and prevention of kidney disease, cardiovascular disease and hypertension. Our research determined that the U.S. was experiencing an epidemic of end-stage kidney disease, pinpointed the incidence of kidney disease and published scholarship on risk factors for kidney disease such as race, diabetes and socioeconomic status. Our Precursors Study has shown that serum cholesterol measured at age 22 years is a predictor for midlife cardiovascular disease, a finding that has influenced policy about cholesterol screening in young adults. We also research health behaviors that lead to hypertension and study how differences in these behaviors affect urban and non-urban populations.

Effective immune responses are critical for control of a variety of infectious disease including bacterial, viral and protozoan infections as well as in protection from development of tumors. Central to the development of an effective immune response is the T lymphocyte which, as part of the adaptive immune system, is central in achieving sterilization and long lasting immunity. While the normal immune responses is tightly regulated there are also notable defects leading to pathologic diseases. Inactivity of tumor antigen-specific T cells, either by suppression or passive ignorance allows tumors to grow and eventually actively suppress the immune response. Conversely, hyperactivation of antigen-specific T cells to self antigens is the underlying basis for many autoimmune diseases including: multiple sclerosis; arthritis; and diabetes. Secondary to their central role in a wide variety of physiologic and pathophysiologic responses my lab takes a broad-based approach to studying T cell responses.

I am a primary care doctor and public health researcher committed to improving women’s health and health care across their lives and improving gender and racial equity.

I am an Associate Professor of Medicine in The Johns Hopkins University School of Medicine, Division of General Internal Medicine. My research focuses on identifying strategies to prevent and manage obesity and type 2 diabetes and cardiovascular disease, particularly among women at highest risk due to pregnancy complications. I conduct pragmatic and community-based randomized controlled trials to test high impact and scalable strategies to reduce excessive weight gain in pregnancy, reduce postpartum weight retention and cardiometabolic risk.

I hold several leadership positions, and I am the Director of Research at Johns Hopkins Community Physicians, the Co-Director of the Johns Hopkins Center for Women’s Health, Sex and Gender Research and a Core Faculty Member of the Welch Center for Prevention, Epidemiology and Clinical Research.